Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Staphylococcus Aureus Infection : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Bacteremia

Burns, Chemical

Endocarditis, Bacterial

Enteroviral Infections

Impetigo

Irritable Bowel Syndrome

Juvenile Rheumatoid Arthritis

Kawasaki Disease

Leptospirosis

Osteomyelitis

Parvovirus B19 Infection

Rheumatic Fever

Rocky Mountain Spotted Fever

Serum Sickness

Streptococcal Infection, Group A

Toxic Shock Syndrome




Patient Education
Women's Health Center

Skin, Hair, and Nails Center

Toxic Shock Syndrome Overview

Toxic Shock Syndrome Causes

Toxic Shock Syndrome Symptoms

Toxic Shock Syndrome Treatment

Boils Overview




Author: Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan, Jr, is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Coauthor(s): Elizabeth P Baorto, MD, MPH, Director, Division of Pediatric Infectious Diseases, Atlantic Health System; David Baorto, MD, PhD, Medical Knowledge Engineer, Department of Medical Informatics, Columbia University Medical Center

Editors: José Rafael Romero, MD, Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus; Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine; Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center

Author and Editor Disclosure

Synonyms and related keywords: abscess, bacteremia, carbuncle, cellulitis, community-acquired methicillin-resistant S aureus, community-associated methicillin-resistant S aureus, CA-MRSA, conjunctivitis, empyema, endocarditis, folliculitis, furuncle, impetigo, methicillin-resistant S aureus, MRSA, methicillin-sensitive S aureus, MSSA, osteomyelitis, pneumonia, Ritter disease, scalded skin syndrome, septic arthritis, Staphylococcus aureus, S aureus, Staphylococcus aureus infection, thrombophlebitis, toxic shock syndrome, TSS, staphylococcal toxic shock syndrome, wound infection

Background

Bacteria of the genus Staphylococcus are gram-positive cocci that are microscopically observed as individual organisms, in pairs, and in irregular, grape-like clusters. The term Staphylococcus is derived from the Greek term staphyle, meaning "a bunch of grapes." Staphylococci are nonmotile, non–spore-forming, and catalase-positive bacteria. The cell wall contains peptidoglycan and teichoic acid. The organisms are resistant to temperatures as high as 50°C, to high salt concentrations, and to drying. Colonies are usually large (6-8 mm in diameter), smooth, and translucent. The colonies of most strains are pigmented, ranging from cream-yellow to orange.

The ability to clot plasma continues to be the most widely used and generally accepted criterion for the identification of Staphylococcus aureus. One such factor, bound coagulase, also known as clumping factor, reacts with fibrinogen to cause organisms to aggregate. Another factor, extracellular staphylocoagulase, reacts with prothrombin to form staphylothrombin, which can convert fibrinogen to fibrin. Approximately 97% of human S aureus isolates possess both of these forms of coagulase.

S aureus is ubiquitous and may be a part of human flora found in the axillae, the inguinal and perineal areas, and the anterior nares. In 2001, von Eiff et al described 3 patterns of carriage: those who always carry a strain, those who carry the organism intermittently with changing strains, and a minority of people who never carry S aureus.1 Persistent carriage is more common in children than in adults.

Wenzel and Perl (1995) found that, among healthy adults, carrier rates of 11-32% were detected in the general population, and a prevalence of 25% was detected in hospital personnel.2 Using pulsed-field gel electrophoresis (PFGE) for molecular typing, von Eiff et al (2001) found that, in most patients with S aureus bacteremia, the isolate from the patient's blood is identical to that found in the anterior nares.1 Curiously, community-associated methicillin-resistant S aureus (CA-MRSA) is rarely found in the anterior nares; rather, it colonizes the skin, particularly in the perineal area. It may also colonize the pharynx, gut, and vagina.

Pathophysiology

The organism may cause disease through tissue invasion and toxin production. The toxins liberated by the organism may have effects at sites distant from the focus of infection or colonization.

Tissue invasion

The postulated sequence of events that leads to infection is initiated with carriage of the organism. The organism is then disseminated via hand carriage to body sites where infection may occur (either through overt breaks in dermal surfaces, such as vascular catheterization or operative incisions, or through less evident breakdown in barrier function, such as eczema or shaving-associated microtrauma).

The hallmark of staphylococcal infection is the abscess, which consists of a fibrin wall surrounded by inflamed tissues enclosing a central core of pus containing organisms and leukocytes. From this focus of infection, the organisms may be disseminated hematogenously, even from the smallest abscess. The ability to elaborate proteolytic enzymes facilitates the process. This may result in pneumonia, bone and joint infection, and infection of the heart valves. In immunocompromised hosts (eg, patients with cancer who are neutropenic and have a central venous line), 20-30% develop serious complications or fatal sepsis following catheter-related S aureus bacteremia.

Persistent deep-seated infections have now been linked to small-colony variants of the organism. This population is more resistant to antibiotics and grows slowly. These organisms have been described in patients with cystic fibrosis and may contribute to the persistence of S aureus in these patients.

Toxin-mediated disease

The organism may also elaborate toxins that can cause specific diseases or syndromes. Enterotoxin-producing strains of S aureus cause one of the most common food-borne illnesses. The most common presentation is acute onset of vomiting and watery diarrhea 2-6 hours after ingestion. The symptoms are usually self-limited. The cause is the proliferation of toxin-producing organisms in uncooked or partially cooked food that an individual carrying the staphylococci has contaminated.

A rare but well-described disorder in neonates and young children is staphylococcal scalded skin syndrome (Ritter disease). The organism produces an exfoliative toxin produced by strains belonging to phage group II. Initial features include fever, erythema, and blisters, which eventually rupture and leave a red base. Gentle shearing forces on intact skin cause the upper epidermis to slip at a plane of cleavage in the skin, which is known as the Nikolsky sign. How the exfoliative toxins produce epidermal splitting has not been fully elucidated.

The most feared manifestation of S aureus toxin production is toxic shock syndrome (TSS). Although first described in children, it was most frequently associated with women using tampons during menstruation. Since the early 1990s, at least half of the cases have not been associated with menstruation. The syndrome is associated with strains that produce the exotoxin TSST-1, but strains that produce enterotoxins B and C may cause 50% of cases of nonmenstrual TSS. These toxins are superantigens, T-cell mitogens that bind directly to invariant regions of major histocompatibility complex class II molecules, causing an expansion of clonal T cells, followed by a massive release of cytokines. This cytokine release mediates the TSS; the resultant pathophysiology mimics that of endotoxic shock.

In a recent worldwide trend, the proportion of infections caused by CA-MRSA has increased. Initially noted in tertiary care centers, these infections are now increasingly common in the community. Resistance to methicillin confers resistance to all penicillinase-resistant penicillins and cephalosporins. This high level of resistance requires the mec gene that encodes penicillin-binding protein 2a. This protein has decreased binding affinity for most penicillins and cephalosporins. Methicillin resistance has a wide variety of phenotypic expression. Heterogeneous resistance, recognized in the first clinical isolates described, is the typical phenotype. In this case, all cells carry the genetic markers of resistance but only a small fraction of them express the phenotype. Less frequent is homogenous resistance, with a single population of cells that are inhibited only through high concentrations of antibiotics.

Methicillin-resistant S aureus (MRSA) was initially described in hospitalized populations. University affiliation and greater number of beds were institutional risk factors. In pediatric centers, number of beds, region, and metropolitan population correlated with increased risk. Since 1996, more patients with CA-MRSA have been described. The strains isolated from these patients are different from typical nosocomial organisms in their susceptibility patterns and in their PFGE characteristics. A clonal population, designated USA-300, has become the predominant circulating organism in most communities. Many of these strains produce the Panton-Valentine leukocidin, which is associated with a tendency to produce abscesses, invasiveness, thrombogenesis, and morbidity and mortality.

More recently, S aureus that is intermediately resistant to vancomycin has been reported in 2 hospitalized patients, which suggests that full resistance to vancomycin may eventually emerge.3 Although the possibility of interspecies transfer of vancomycin-resistance genes from vancomycin-resistant Enterococcus was originally considered as the cause of this phenomenon, none of the species isolated have carried vanA, vanB, vanC1, vanC2, or vanC3 genes. Of note, the clinical isolates with intermediate resistance to vancomycin were from patients who had undergone prolonged vancomycin therapy for MRSA. Morphologically, these isolates were found to have increased extracellular material associated with the cell wall that may have been selected for during a prolonged antibiotic course.

Frequency

United States

Numbers of both community-associated and hospital-acquired infections have increased in the past 20 years. From 1990-1992, data from the National Nosocomial Infections Surveillance System for the Centers for Disease Control and Prevention (CDC) revealed that S aureus was the most common cause of nosocomial pneumonia and operative wound infections and the second most common cause of nosocomial bloodstream infections.

Frequency of antibiotic resistance: In a disturbing trend, antibiotic resistance among these isolates has increased because of antibiotic pressure. Currently, less than 5% of clinical isolates remain sensitive to penicillin. Resistance to penicillin was reported as early as 1942 and is mediated by beta-lactamase, a serine protease that hydrolyzes the lactam ring. In the 1980s, MRSA emerged as a prominent hospital-based infection; consequently, the use of vancomycin increased. A CDC survey revealed that the proportion of methicillin-resistant isolates with sensitivity only to vancomycin increased from 22.8% in 1987 to 56.2% in 1997.4

Mortality/Morbidity

Morbidity and mortality from S aureus infection widely varies depending on the clinical entity. Although mortality is low in children with scalded skin syndrome, most fatalities are associated with delay in diagnosis.

Sex

The male-to-female ratio of skeletal infections is 2:1, mostly because boys are more likely to experience traumatic events.



History

  • Skin and soft tissue (impetigo): Typically, this starts as a small area of erythema that progresses into bullae (filled with cloudy fluid) that rupture and heal with the formation of a honey-colored crust. Although group A Streptococcus was once considered the primary agent, Staphylococcus aureus has become the major pathogen since the 1980s. S aureus exclusively causes bullous impetigo, which is observed less frequently in the United States. This form of disease seems to arise from healthy-appearing skin. The bullae rupture, leaving a denuded area with a varnish-like coating.
  • Scalded skin syndrome (Ritter disease): An exfoliative toxin (see Toxin-mediated disease) causes this relatively rare syndrome, which takes the form of superficial fragile blisters that burst, leaving a tender base. The patient is often febrile and, occasionally, has mucopurulent eye discharge. This diagnosis should be made carefully, because scalded skin syndrome may be mistaken for erythema multiforme or toxic epidermal necrolysis, which can be treated with corticosteroids. Misdiagnosis delays treatment and allows exfoliation to progress, and corticosteroid therapy may potentiate bacterial superinfection. Although the mortality rate is low in children with this entity, most fatalities are associated with delay in diagnosis.
  • Folliculitis, furuncle, and carbuncle: These are increasingly severe staphylococcal skin infections. Folliculitis is a tender pustule that involves the hair follicle. A furuncle involves both the skin and the subcutaneous tissues in areas with hair follicles, such as the neck, axillae, and buttocks. They are actually small abscesses characterized by exuding purulent material from a single opening. A carbuncle is an aggregate of connected furuncles and has several pustular openings. Skin infections may be self-limited, but they can also disseminate hematogenously and cause life-threatening septicemia.
  • Bone infections (osteomyelitis)
    • Children often present with sudden onset of fever and bony tenderness or a limp. The pain may be throbbing and severe; however, presentation in neonates can be subtle. Infants may appear well except for failure to move an extremity or pain on movement. Redness or swelling indicates that infection has spread into the subperiosteal space. Rupture of a focus of osteomyelitis into joint space can result in septic arthritis. This is often observed in neonates.
    • Children with vertebral osteomyelitis present with back pain, and those younger than 3 years present with refusal to walk or with a limp. Occasionally, children with vertebral osteomyelitis present with incontinence. Children with discitis tend to present with less fever and often appear less ill than children with vertebral osteomyelitis.
  • Septic arthritis: Typical findings include decreased range of motion, warmth, erythema, and tenderness of the joint with constitutional symptoms and fever. Infants (in whom the hip is the most commonly involved joint) are an exception, as these signs may be absent. The child typically lies with the involved joint abducted and externally rotated. Because pain fibers are located within the joint capsule, movements that compress the head of the femur into the acetabulum (eg, changing a diaper) cause pain. A portal of infection is almost never found, and the infection is nearly always unilateral. Patients with infection of the sacroiliac joint present with tenderness elicited during digital rectal examination and with pain during flexion, abduction, and external rotation of the hip.
  • Endocarditis: The initial presentation of patients with S aureus endocarditis is fever and malaise. However, the disease has a more rapid onset than that caused by less virulent pathogens. Notably, on initial presentation, the usual physical stigmata are absent. Endocarditis may also involve healthy valves. For more detail, please see Endocarditis, Bacterial.
  • TSS
    • Staphylococcal TSS is a potentially life-threatening systemic bacterial intoxication. Case definition includes fever, diffuse macular erythema, and hypotension, with involvement of 3 or more of the following organ systems:
      • GI - Emesis or diarrhea appears at the time of illness. Diarrhea is secretory and profuse, and is found in almost all patients with TSS but is uncommon in patients in septic shock.
      • Muscular - Severe myalgia or elevated creatine kinase (CK) levels are observed. Myalgia may be one of the earliest manifestations of the disease.
      • Renal - Elevation of BUN or creatinine levels or more than 5 WBCs per high-power field in the absence of a urinary tract infection is observed.
      • Hepatic levels of bilirubin, serum glutamic-oxaloacetic transaminase (aspartate aminotransferase), and serum glutamic-pyruvic transaminase (alanine aminotransferase) are twice the upper limit of the reference range.
      • Hematologic – The platelet count is less than 100,000/mL.
      • Nervous system – Features include disorientation and alteration in consciousness with the absence of focal neurologic signs when fever and hypotension are absent.
    • A probable case of TSS involves 5 of the above 6 findings.
    • A confirmed case of TSS involves all 6 findings.
    • The most striking aspect of the disease is the rapidity with which it can progress in a previously healthy individual of any age. This is especially true in postsurgical patients, particularly following nasal surgery, because this is an area commonly colonized with S aureus. Late-onset dermatologic findings include a red and pruritic maculopapular rash, desquamation of the fingers and toes, and telogen effluvium (see Toxic Shock Syndrome).
  • Pneumonia: Cases of rapidly progressive and fatal staphylococcal pneumonia still occur, although they were much more common in the 1950s and early 1960s, when S aureus phage type 80/81 caused frequent disease in infants. Staphylococcal pneumonia most commonly occurs in infants, young children, and patients who are debilitated. This is a rapidly progressive disease. Patients with primary staphylococcal pneumonia present with a short prodrome of fever followed by rapid onset of respiratory distress, which may include tachypnea, retractions, and cyanosis. Patients may also have prominent GI tract symptoms. Staphylococcal pneumonia may also develop after influenza infection. Typically, the child seems to recover from a febrile illness only to once again develop an increasing fever and the symptoms mentioned above.
  • Thrombophlebitis: Usually occurring in a hospitalized patient, thrombophlebitis is characterized by fever, pain, and, occasionally, erythema at the insertion site of an intravenous catheter. Occasionally, pus is expressed. Severe suppurative thrombophlebitis may occur in burn patients, with fewer than half of diagnoses made while the patients are alive.
  • Deep tissue abscess and infection: Muscles (myositis and pyomyositis) and organs can become infected, including the parotid gland, eyes, liver, spleen, and kidneys. These infections typically cause fever with or without localizing pain.

Physical

  • Skin and soft tissue (impetigo): The infection initially appears as a small area of erythema. Bullae (ie, blisterlike lesions filled with cloudy fluid) appear as the disease progresses. As bullae heal, a honey-colored crust develops.
  • Scalded skin syndrome (Ritter disease): Examination reveals superficial, fragile blisters that burst, leaving a tender base. Skin sloughs easily when touched, a condition termed the Nikolsky sign. Fever is often present, and mucopurulent eye discharge may be observed. As discussed above, the infection is often mistaken for erythema multiforme or toxic epidermal necrolysis. Misdiagnosis must be avoided.
  • Folliculitis, furuncle, and carbuncle: Folliculitis is the appearance of a tender pustule involving a hair follicle. A furuncle is an apparent small abscess that exudes purulent material from a single opening. A carbuncle is an aggregate of furuncles with several openings.
  • Bone infections (osteomyelitis): Fever, bony tenderness, or a limp indicate bone infections. Infants may appear well except for failure to move an extremity or pain on movement. Children with vertebral osteomyelitis present with back pain, and those younger than 3 years present with refusal to walk or with a limp. Occasionally, children with vertebral osteomyelitis have incontinence as a presenting symptom. Children with discitis tend to present with less fever and often appear less ill than children with vertebral osteomyelitis.
  • Septic arthritis: Examination reveals warmth, erythema, and tenderness of the joint. Constitutional symptoms and fever are frequently observed. These findings may be absent in an infant. Children with infection of the sacroiliac joint present with tenderness elicited during digital rectal examination.
  • Endocarditis: The clinical syndrome widely varies and may involve multiple organs. S aureus infection usually results in an acute course but may involve subacute disease. Most patients present with high fever. Chills and sweats and a new or worsened murmur may occur. Peripheral emboli such as Osler nodes, subungual hemorrhages, Janeway lesions, and Roth spots may be present. Other embolic phenomena may occur.
  • TSS: TSS involves a fever of 38.9°C or higher. Hypotension occurs, either with blood pressure below the fifth percentile for age or with an orthostatic (lying to sitting) drop in diastolic blood pressure greater than or equal to 15 mm Hg. A diffuse, erythroderma-like rash is present. Conjunctival or vaginal hyperemia may be present. Patients may have altered sensorium, even when normotensive, or may be delirious, disoriented, or agitated without focal signs. Reddened lips and tongue may be observed. Later, on recovery, desquamation of hands and feet may occur; occasionally, alopecia occurs later.
  • Pneumonia: Fever is present. Findings of respiratory distress include tachypnea, cyanosis, grunting, and retractions. Vomiting and abdominal distension occur. Clinical deterioration is rapid.
  • Thrombophlebitis: Patients usually have a fever and, occasionally, have cutaneous involvement such as erythema, induration, or tenderness. Occasionally, pus is expressed at the insertion site of the catheter. The exit site often does not show signs of infection. Establishing infection of an intravascular device as the cause of fever in a hospitalized patient is a diagnosis of exclusion.
  • Deep tissue abscess and infection: Localizing tenderness may be present, as may signs of inflammation.

Causes

  • Skin and soft tissue (impetigo): Often occurring in young children, impetigo is spread within families and through close physical contact. Impetigo is more prevalent in warm, humid climates because of more opportunities for insect bites and cutaneous trauma. Impetigo may also be a complication of Varicella. Diagnosis is usually made based on the characteristic appearance of the lesions. Bullous impetigo may also occur in endemic and epidemic patterns. Nursery outbreaks have been described, and some cases in infants have progressed to scalded skin syndrome or Ritter disease (described in History).
  • Folliculitis, furuncle, and carbuncle: Recurrent staphylococcal skin infections develop in certain patients, such as those with impaired neutrophil function (eg, those with chronic granulomatous disease), patients with atopy and chronic eczema, and those with impaired circulation and diabetes mellitus. However, most patients with recurrent furunculosis are colonized with CA-MRSA but are otherwise healthy. Thus, an evaluation of the immune system in these individuals is seldom useful.
  • Bone and joint infections (osteomyelitis): Osteomyelitis typically occurs in children prior to the age of epiphyseal closure. Osteomyelitis typically originates in the metaphysis of long bones in the region of most rapid growth. Osteomyelitis usually involves (in order of frequency) the lower end of the femur, the upper end of the tibia and humerus, and the radius. Most bone and joint infections result from hematogenous spread, but significant blunt trauma is a preceding event in approximately one third of cases. In addition, penetrating wounds, compound fractures, and orthopedic appliances may introduce microbial infection directly into bone. Notably, the male-to-female ratio of skeletal infections is 2:1, mostly because boys are more likely to experience traumatic events.
  • Septic arthritis: Staphylococci are frequent etiologic agents of septic arthritis and, since the era of successful vaccination for Haemophilus influenzae, are now more predominant in younger age groups. Bacteria can enter the joint space through hematogenous spread, direct inoculation, or contiguous spread of infection. Because the synovial membrane has a high effective blood flow, a large number of bacteria may be delivered to the joint during a period of bacteremia. Inoculation can occur when a joint is punctured with a contaminated object, and many clinical studies reveal that the knee is more likely to be punctured. In the postantibiotic era, contiguous spread has been rare, with the exception of neonatal osteomyelitis.
  • Endocarditis: Fortunately, S aureus endocarditis is rare in pediatric patients. It often involves adolescent intravenous drug users who do not have antecedent valvular disease. These patients usually present with right-sided disease with evidence of pulmonary disease, such as pulmonary abscesses or shifting infiltrates. In children with preexisting heart disease, endocarditis is often temporally related to cardiac surgery or catheterization. Children with prosthetic valves are particularly vulnerable because of the organism’s propensity to adhere to foreign materials. In addition, patients with indwelling vascular access devices are at risk, because infections from the skin can seed the catheter.
  • TSS
    • Infection with toxin-producing S aureus in the absence of protective antibody is an antecedent. Younger patients may be at increased risk because they lack the protective antibodies to the enterotoxins and other exotoxins responsible for producing this clinical syndrome. However, other factors may be involved; Jacobsen et al (1989) demonstrated in a small study that not all patients without antibody develop true TSS when infected with a toxin-producing strain of the organism.5
    • Approximately 25% of all S aureus strains are toxigenic, and, at any time, roughly 4-10% of healthy individuals are colonized with these strains. In the 1980s, the disease was associated with the use of highly absorbent tampons in women during menstruation. Currently, many cases observed are nonmenstrual (eg, localized infections, surgery, infected varicella lesions, insect bites), and these now account for one third of all cases. These patients carry a higher mortality rate than those with menstrual TSS.
  • Pneumonia: The primary form occurs without an extrapulmonary focus, presumably through direct inoculation to the lungs, and the secondary form results from hematogenous seeding of the lungs during endocarditis or bacteremia. Predisposing factors include infancy, chronic illness, and viral respiratory disease such as influenza. Patients with head injury and trauma who have nasopharyngeal carriage of S aureus are at increased risk of S aureus pneumonia.
  • Thrombophlebitis: The causes are associated with infusion, including infected intravenous catheters and needles. The common point of entry for infection related to intravascular devices is the insertion site along the outside of the device.
  • Deep tissue abscess and infection: These typically result from hematogenous seeding, although myositis or pyomyositis can result from contiguous spread of infection and endophthalmitis can follow trauma (injury or iatrogenic), for example.

The differential diagnoses of staphylococcal infections include the following:

  • Impetigo - None
  • Bullous impetigo
    • Pemphigus
    • Pemphigoid
    • Burn
    • Stevens-Johnson syndrome
    • Dermatitis herpetiformis
  • Scalded skin syndrome (Ritter disease)
    • Nonaccidental injury
    • Scalding
    • Abrasion trauma
    • Sunburn
    • Erythema multiforme
    • Toxic epidermal necrolysis
  • Bone and joint infections
    • Bone infarction (in patients with sickle cell disease)
    • Toxic synovitis
    • Leukemia
  • Septic arthritis
    • Trauma
    • Deep cellulitis
    • Henoch-Schönlein purpura
    • Slipped capital femoral epiphysis
    • Legg-Calve-Perthes disease
    • Leukemia
    • Toxic synovitis
    • Metabolic diseases affecting joints (Ochronosis)
  • Endocarditis - Bacteremia
  • TSS
    • Staphylococcal scalded skin syndrome
    • Meningococcemia
    • Rubeola
    • Adenoviral infections
    • Dengue fever
    • Severe allergic drug reactions



Bacteremia
Burns, Chemical
Endocarditis, Bacterial
Enteroviral Infections
Impetigo
Irritable Bowel Syndrome
Juvenile Rheumatoid Arthritis
Kawasaki Disease
Leptospirosis
Osteomyelitis
Parvovirus B19 Infection
Rheumatic Fever
Rocky Mountain Spotted Fever
Serum Sickness
Streptococcal Infection, Group A
Toxic Shock Syndrome


Lab Studies

An erythromycin-induction test, or D-test, should always be performed with staphylococcal sensitivities to reveal inducible clindamycin resistance among CA-MRSA.

  • Folliculitis, furuncle, and carbuncle: Make the diagnosis based on clinical appearance and, occasionally, on results of aspiration or incision and culture of purulent material from the lesion.
  • Osteomyelitis: Blood culture results are positive in only 30-50% of pediatric patients. Therefore, cultures of bone aspirate are useful in obtaining the organism and planning for long-term therapy. In addition, C-reactive protein levels and erythrocyte sedimentation rate are generally elevated in acute disease.
  • Septic arthritis: Examination of joint fluid, when obtained, is the primary means of diagnosis; the fluid should be sent to the laboratory for Gram stain and culture. In addition, the number and type of leukocytes should be determined. Median cell count in bacterial arthritis is 60.5 X 109 cells with a neutrophil predominance of greater than 75%. Often, synovial fluid glucose levels are low. Yield of culture may be improved by directly inoculating synovial fluid into blood culture bottles.
  • Endocarditis: The most important diagnostic procedure is the blood culture. Blood should be injected into hypertonic media if the patient has been exposed to antibiotics. Obtaining 3-5 sets of large-volume blood cultures within the first 24 hours is recommended.
  • Pneumonia: Blood culture findings for Staphylococcus aureus are more likely to be positive in secondary disease than in primary disease (90% vs 20%). Because blood culture results are often negative, an adequate respiratory tract specimen should be obtained prior to initiating therapy; specimens may include endotracheal sampling, pleural fluid, or lung tap. Sputum is not considered adequate because the organism is frequently present in the upper respiratory secretions of healthy individuals.
  • Thrombophlebitis: Although treatment is occasionally controversial, obtaining a blood culture through the intravenous line and a peripheral blood culture is usually recommended.

Imaging Studies

  • Osteomyelitis: On plain film radiographs, destructive bone changes are usually observed 2 weeks after infection. This is because a 30-50% reduction in bone calcium content is required before an osteolytic lesion is visible. The clinical diagnosis of osteomyelitis is most often supported by findings on bone scan with technetium Tc99m–labeled diphosphonate. Increased tracer uptake reflects the inflammatory process in the bone lesion. However, this modality is not as useful in neonates or after trauma or surgery. MRI is the best imaging modality for defining purulent collections and for planning surgery.
  • Septic arthritis: Plain radiographs show capsular swelling. They are most useful in revealing other causes of hip pain, such as Legg-Calve-Perthes disease. Radiographs should be obtained with the child in the frog leg position as well as with the legs extended and slightly internally rotated. Displacement of gluteal fat lines because of the swelling of the joint capsule is an early radiologic sign of septic arthritis. If a bone scan is performed, increased uptake on either side of the joint is visible. As pyogenic sacroiliitis is difficult to diagnose, the radiologic method of choice is MRI or CT scanning.
  • Endocarditis: Echocardiography is a valuable adjunct. Two-dimensional echocardiography is more sensitive than the M-mode technique, and it has been used to reveal vegetations in patients with negative culture results. However, because of variable sensitivity, a negative finding does not exclude endocarditis. Transesophageal echocardiography is more sensitive than transthoracic echocardiography in the detection of intracardiac vegetations.
  • Pneumonia: No radiologic features are highly specific, but the chest radiograph may provide information, especially in demonstrating its progression. Radiographs of patients with primary staphylococcal pneumonia may reveal unilateral consolidation, while patients with secondary staphylococcal pneumonia are more likely to demonstrate bilateral infiltrates on radiographs. Early in the disease course, the chest radiograph may reveal minimal infiltrates, but, within hours, they rapidly progress. Pleural effusion, pneumatoceles, and pneumothorax are also common.

Histologic Findings

  • For scalded skin syndrome (Ritter disease), histologic examination of a skin biopsy specimen is the most helpful, because demonstration of midepidermal separation at the zona granulosa is diagnostic of this entity and excludes erythema multiforme in which dermoepidermal cleavage occurs.



Medical Care

Because CA-MRSA causes more than one half of all staphylococcal infections in most communities, empiric therapy with penicillins or cephalosporins is inadequate. Some experts recommend combination therapy with a penicillinase-resistant penicillin or cephalosporin (in case the organism is methicillin-sensitive Staphylococcus aureus [MSSA]) and clindamycin or a quinolone. Others suggest use of clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, or a quinolone. Finally, because of concerns about induction of resistance, some recommend using TMP-SMX and rifampin in combination, rather than singly.

  • Impetigo, folliculitis, furuncle, carbuncle: Impetigo and other minor skin infections (ie, superficial or localized infections) may be treated with a topical agent such as mupirocin or retapamulin. However, most CA-MRSA strains are or readily become resistant to mupirocin. More extensive or serious skin disease and bullous impetigo are treated with oral antistaphylococcal agents, as noted above.
  • Scalded skin syndrome (Ritter disease): As with any S aureus toxin–mediated disease, treatment should aim to eradicate the focus of infection and end toxin production. Administer large doses of intravenous antistaphylococcal agents, such as oxacillin (150 mg/kg/d), or a first-generation cephalosporin, such as cefazolin (100 mg/kg/d). In vitro, clindamycin has been shown to inhibit the synthesis of TSST-1 and is extremely effective in combination with one of the agents mentioned above. Children with denuded skin should be touched as little as possible. Topical antimicrobial agents have little use, because skin damage is self-limited once systemic antibiotics are administered.
  • Osteomyelitis: Empirically, initiating a semisynthetic penicillin (eg, oxacillin [150 mg/kg/d]) and clindamycin (30-40 mg/kg/d) is a good choice for most cases of community-acquired osteomyelitis. In patients with allergy to penicillin, a first-generation cephalosporin and clindamycin (30-40 mg/kg/d) are an excellent alternative. Use vancomycin or linezolid when the other drugs mentioned are absolutely not tolerated or when resistance or the clinical course dictates. The duration of therapy is a controversial topic in the literature, but the consensus among multiple authors is that the minimum effective treatment time is 4-6 weeks. A switch to oral therapy is acceptable if the child is able to take oral antibiotics, is afebrile, and if he or she has demonstrated a good clinical response to parenteral antibiotics.
  • Septic arthritis: As in osteomyelitis, initiate an appropriate antistaphylococcal drug (eg, oxacillin, which is penicillinase resistant; clindamycin; cefazolin) parenterally. These antibiotics readily reach joint fluid, and the concentration in the joint fluid is 30% of the serum value. Therapy usually continues for at least 4 weeks. Duration of parenteral therapy is often debated. Some authors have demonstrated efficacy with 1 week of parenteral therapy followed with 3 weeks of oral therapy. Consider a switch to oral therapy based on the considerations mentioned above. Joint fluid that reaccumulates should be removed, and a sample should be cultured to assess the efficacy of therapy and to make the patient more comfortable.
  • Endocarditis
    • Duration of therapy for endocarditis, which is a life-threatening infection, is at least 4 weeks.
    • The combination of a beta-lactam and an aminoglycoside is advocated, because it increases bacterial killing in vitro and in animal models of endocarditis. In patients with MRSA, combinations of vancomycin with aminoglycosides should be used.
    • Rifampin, because of its lipid solubility, is another potent agent when used in combination with nafcillin and gentamicin or vancomycin and gentamicin, especially in patients with prosthetic valve endocarditis. Rifampin should never be used alone because resistance can develop.
    • The response to therapy is usually slow, and patients may continue to have bacteremia, fever, and leukocytosis for at least a week after therapy is initiated.
    • Some authors recommend obtaining blood cultures after the end of therapy.
    • Treatment with antibiotics is specific to the etiologic agent and its characteristics. For more information, see Endocarditis, Bacterial.

Surgical Care

  • Osteomyelitis: Surgery is usually indicated to drain purulent material from the subperiosteal space or if infected foreign material is present.
  • Septic arthritis: In an infant, septic arthritis of the hip and shoulder is a surgical emergency; these joints should be drained as soon as possible to prevent bony destruction. In addition, if a large amount of fibrin, tissue debris, or loculation is present, preventing adequate drainage with needle aspiration, the joint should be surgically drained.
  • Endocarditis: If endocarditis occurs in the presence of an intracardiac foreign body, it may require removal.
  • TSS: All potential foci of infection should be explored and surgically drained.
  • Thrombophlebitis: Remove the infected intravenous line in patients who are immunocompromised or severely ill or when infection is impossible to eradicate medically.



The major antibiotics active against the staphylococcal organism are presented here.

Drug Category: Antistaphylococcal antibiotics

Serious staphylococcal infections require treatment with parenteral penicillinase-resistant penicillin (eg, nafcillin, oxacillin) or first-generation or second-generation cephalosporins (eg, cephalexin, cefuroxime) plus clindamycin. Vancomycin is reserved for staphylococcal strains that are resistant to penicillinase-resistant penicillins (ie, MRSA) and clindamycin, or for when the patient has potentially life-threatening infection or intoxication. Mupirocin or retapamulin may be used for superficial localized infections (ie, impetigo).

Drug NameDicloxacillin
DescriptionBinds to one or more penicillin-binding proteins, which, in turn, inhibits synthesis of bacterial cell walls. For treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when staphylococcal infection is suspected.
Adult Dose125-500 mg PO q6h
Pediatric Dose<40 kilograms: 12.5-50 mg/kg/d PO divided q6h; doses up to 50-100 mg/kg/d have been used for PO therapy for osteomyelitis
>40 kilograms: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsDecreases efficacy of PO contraceptives; may decrease effects of anticoagulants; probenecid and disulfiram may increase penicillin levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsProlonged elimination in neonates; toxicity may increase with renal dysfunction

Drug NameOxacillin
DescriptionBactericidal antibiotic that inhibits cell wall synthesis. Used in the treatment of infections caused by penicillinase-producing staphylococci.
Adult Dose0.25-1 g IV q6h
Pediatric Dose150 mg/kg/d IV divided qid
ContraindicationsDocumented hypersensitivity
InteractionsOxacillin decreases effects of contraceptives and tetracycline; when administered concomitantly with disulfiram and probenecid, may increase oxacillin levels; increases anticoagulant effect with large IV doses
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsDecreased elimination in neonates; can cause elevations in levels of transaminases with prolonged use

Drug NameNafcillin
DescriptionInitial therapy for suspected penicillin G–resistant staphylococcal infections. Use parenteral therapy initially in severe infections. Change to PO therapy as condition warrants.
Adult Dose0.5-1 g IV/IM q4-6h
Pediatric DoseNeonates:
<1200 grams or <7 days and 1200-2000 grams: 50 mg/kg/d IV divided q12h
<7 days and >2000 grams or >7 days and 1200-2000 grams: 75 mg/kg/d IV divided q8h
>7 days and >2000 grams: 100 mg/kg/d IV divided q6h
Children:
100-200 mg/kg/d IV divided qid; not to exceed 12 g/d
Reduce dose by 50% in renal or hepatic impairment
ContraindicationsDocumented hypersensitivity
InteractionsCYP450 3A4 inducer; probenecid may decrease elimination of nafcillin; nafcillin may decrease half-life of warfarin and may decrease cyclosporine serum concentrations or interfere with the cyclosporine assay
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsElimination decreased in neonates; avoid during first 2 wk of life; monitor CBC count with prolonged use; may cause thrombophlebitis

Drug NameCephalexin (Keflex)
DescriptionFirst-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora.
Adult Dose250-500 mg PO q6h; not to exceed 4 g/d
Pediatric Dose25-100 mg/kg/d PO divided q6h; not to exceed 4 g/d
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase and prolong cephalosporin plasma levels by competitively inhibiting renal tubular secretion; coadministration with aminoglycosides theoretically increases risk of nephrotoxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameCefuroxime (Ceftin oral, Kefurox injection)
DescriptionBroad-spectrum cephalosporin most closely resembling the second-generation cephalosporins. Cefuroxime is stable against beta-lactamase–producing organisms.
Adult Dose250-500 mg PO bid; alternatively, 1 g IV q8h
Pediatric DoseSerious infections: 150 mg/kg/d IV divided q8h
Impetigo:
250-mg tab PO q12h
30 mg/kg/d PO susp divided bid; not to exceed 1 g/d
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase and prolong cephalosporin plasma levels by competitively inhibiting renal tubular secretion; aminoglycosides may increase nephrotoxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsPeriodically monitor renal function and CBC count; adjust dose or frequency with renal insufficiency (high doses may cause CNS toxicity); bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

Drug NameCefazolin
DescriptionFirst-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin structure coverage.
Adult Dose0.5-2 g IV q6-8h; not to exceed 12 g/d
Pediatric Dose50-100 mg/kg/d IV divided q8h; not to exceed 6 g/d
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid prolongs effect of cefazolin; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine-dip test results for glucose
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsMonitor renal function parameters when used with other nephrotoxic drugs; monitor CBC count with prolonged use; dosing in renal impairment: administer q24h if CrCl <10 mL/min, administer q12h if CrCl 10-30 mL/min

Drug NameAmoxicillin and clavulanate (Augmentin)
DescriptionDrug combination treats bacteria resistant to beta-lactam antibiotics. For children >3 mo, base dosage regimen on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (ie, 250/125) versus 250-mg chewable tab (ie, 250/62.5), do not use 250-mg tab until child is >40 kg.
Adult Dose250-500 mg PO q8h; not to exceed 2 g/d
Pediatric Dose<3 months: 30 mg (based on amoxicillin component) per kg/d PO divided q12h
Use 125 mg/5 mL PO susp
>3 months and <40 kilograms: 45 mg (based on amoxicillin component) per kg/d PO divided bid/tid
>40 kilograms: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsIncreased risk of amoxicillin rash with concurrent allopurinol; probenecid and disulfiram may increase penicillin levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsIncreased risk of maculopapular rash with concurrent EBV infection, CMV infection, or acute lymphocytic leukemia

Drug NameVancomycin (Lyphocin, Vancocin, Vancoled)
DescriptionPotent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated in patients who are unable to receive or who have not responded to penicillins and cephalosporins or for infections with resistant staphylococci. Use CrCl to adjust dose in patients diagnosed with renal impairment.
Adult Dose0.5 g IV q6h or 1 g IV q24h
Pediatric DoseNeonates:
<7 days and >2000 grams: 30 mg/kg/d IV divided q12h
>7 days and >2000 grams: 45 mg/kg/d IV divided q8h
<1 month and <1200 grams: 15 mg/kg/d IV q24h
<1 month and 1200-2000 grams: 20-30 mg/kg/d IV divided q12-18h
Infants >1 month and children: 40 mg/kg/d IV divided q8h
Seriously ill cancer patients and patients with suspected CNS infection: 60 mg/kg/d IV divided q6h
The necessity of monitoring drug levels is debated; to achieve an adequate therapeutic level in severe infections, the upper range of the peak (40 mcg/mL) should be reached
ContraindicationsDocumented hypersensitivity; avoid using with prior hearing loss
InteractionsErythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsUse with caution in patients with renal impairment or on other nephrotoxic or ototoxic drugs; may cause facial flushing due to histamine release (ie, red man syndrome); flushing usually resolves by slowing IV infusion to administration over 2 h and by administering antihistamines; adjust daily dosing frequency in renal impairment (ie, monitor serum levels and CrCl)

Drug NameClindamycin (Cleocin)
DescriptionLincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, arresting RNA-dependent protein synthesis.
Adult Dose150-450 mg PO q6h
1.2-1.8 g/d IV divided bid/qid; may increase dose, not to exceed 4.8 g/d
Pediatric Dose10-30 mg/kg/d PO divided q6-8h
25-40 mg/kg/d IV divided q6-8h; not to exceed 4.8 g/d
ContraindicationsDocumented hypersensitivity
InteractionsIncreases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis through allowing overgrowth of Clostridium difficile (inform patient to report severe diarrhea immediately)

Drug NameDaptomycin (Cubicin)
DescriptionFirst of new antibiotic class termed cyclic lipopeptides. Binds to bacterial membranes and causes rapid membrane potential depolarization, thereby inhibiting protein, DNA, and RNA synthesis, and, ultimately, causing cell death. Indicated to treat complicated skin and skin structure infections caused by S aureus (including methicillin-resistant strains), S pyogenes, S agalactiae, S dysgalactiae, and E faecalis (vancomycin-susceptible strains only). Indicated for skin and skin structure infections.
Adult DoseCrCl >30 mL/min: 4 mg/kg IV q24h infused over 30 min
CrCl <30 mL/min: 4 mg/kg IV q48h (including hemodialysis or CAPD)
Pediatric Dose<18 years: Not established
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with tobramycin slightly increase daptomycin Cmax and AUC and decreases tobramycin Cmax and AUC; may experience additive effects with other drugs causing myopathy (eg, HMG CoA reductase inhibitors)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDecrease dose with renal function <30 mL/min; pseudomembranous colitis may occur; may cause muscle pain or weakness; monitor CPK levels and discontinue daptomycin upon elevated CPK and unexplained myopathy or marked CPK elevation (10X upper limit of reference range); not indicated for pneumonia (higher death rate in daptomycin-treated patients during phase III trials); not compatible with dextrose-containing solutions

Drug NameLinezolid (Zyvox)
DescriptionPrevents formation of functional 70S initiation complex, which is essential for bacterial translation process. Bacteriostatic against staphylococci.
Adult Dose400-600 mg PO/IV q12h
Pediatric DosePreterm neonate <7 days: 10 mg/kg PO/IV q12h
Term neonates-12 years: 10 mg/kg PO/IV q8h
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsMay cause hypertension when used concomitantly with adrenergic agents including pseudoephedrine, sympathomimetic agents, vasopressor or dopaminergic agents (reduce dose of dopamine or epinephrine if concurrent use required); serotonin syndrome may occur if used concomitantly with serotonergic agents including tricyclic antidepressants, meperidine, dextromethorphan, trazodone, venlafaxine, and SSRIs; may cause myelosuppression or pseudomembranous colitis inhibitors
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsHas mild MAOI properties and may have the same interactions as other MAOIs; caution in uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism; caution in patients who are at increased risk of bleeding, have preexisting thrombocytopenia, receive concomitant medications that may decrease platelet count or function, or who may require >2 wk of therapy (monitor platelet counts); unnecessary use may lead to development of drug resistance; may cause peripheral or optic neuropathy

Drug NameRifampin (Rifadin injection/oral, Rimactane oral)
DescriptionInhibits RNA synthesis in bacteria by binding to beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription.
Adult DoseS aureus: 600 mg/d PO/IV with other antibiotics
Pediatric DoseS aureus: 15 mg/kg/d PO/IV divided q12h with other antibiotics
ContraindicationsDocumented hypersensitivity
InteractionsInduces microsomal enzymes, which may decrease effects of acetaminophen, PO anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, PO contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, digoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, or tocainide; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid or pyrazinamide may result in higher rate of hepatotoxicity than with either agent alone (discontinue one or both agents if alterations in LFT results occur); additive hepatotoxic effect with halothane
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMonitor liver function periodically; stains body fluids orange; soft contact lenses may be permanently stained; obtain CBC counts and baseline clinical chemistries prior to and throughout therapy; in liver disease, weigh benefits against risk of further liver damage; interruption of therapy and high-dose intermittent therapy are associated with thrombocytopenia that is reversible if therapy is discontinued as soon as purpura occurs; if treatment is continued or resumed after appearance of purpura, cerebral hemorrhage or death may occur

Drug NameSulfamethoxazole and trimethoprim (Bactrim, Septra)
DescriptionInhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.
Adult Dose160/800 mg PO q12h
Pediatric Dose<2 years: Do not administer
>2 years: 6-12 mg of trimethoprim/kg/d in 2 doses
ContraindicationsDocumented hypersensitivity; megaloblastic anemia due to folate deficiency; age <2 mo
InteractionsMay increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDo not use during last trimester of pregnancy because of potential toxicity to newborn (eg, jaundice, hemolytic anemia, kernicterus)
Dosage adjustments (adult adjustments)
CrCl (mL/min) 80-50: Recommended IV dose q18h
CrCl 50-10: Recommended IV dose q24h
CrCl <10: Not recommended
HD: 4-5 mg/kg after HD
During peritoneal dialysis: 0.16-0.8 g q48h
Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBC count frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, those who have chronic alcoholism, who are elderly, who are receiving anticonvulsant therapy, or who have malabsorption syndrome); hemolysis may occur in individuals deficient in G-6-PD; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation

Drug NameMupirocin (Bactroban)
DescriptionFor elimination of S aureus. Inhibits bacterial growth by inhibiting RNA and protein synthesis.
Adult DoseApply small amount topically to affected area 2-5 times per d for 5-14 d
Apply intranasal ointment 2-4 times per d and topical cream or ointment 3-5 times per d
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity; hypersensitivity to polyethylene glycol
InteractionsConcurrent intranasal administration of other medication not studied
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsFor topical use only; avoid contact with eyes; patients with burns or open wounds can absorb toxic levels of polyethylene glycol; may irritate mucous membranes; overgrowth of nonsusceptible organisms can result with prolonged use

Drug NameRetapamulin (Altabax)
DescriptionTopical antibiotic available as a 1% ointment. First of new antibiotic class called pleuromutilins. Inhibits protein synthesis by binding to 50S subunit on ribosome. Indicated for impetigo caused by Staphylococcus aureus or Streptococcus pyogenes.
Adult DoseApply topically to affected site bid for 5 d
Pediatric Dose<9 months: Not established
>9 months: Apply as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone known
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay cause irritation at application site (1.4%); avoid application to eye area; keep out of reach of children

Drug Category: Blood products

These agents stimulate an immune response and offer transient protection while the host immune system develops antibodies.

Drug NameImmune globulin, intravenous (Carimune, Gamunex, Polygam S/D)
DescriptionActions include neutralizing circulating myelin antibodies through anti-idiotypic antibodies, down-regulating proinflammatory cytokines (including interferon gamma), blocking Fc receptors on macrophages, suppressing inducer T and B cells, and augmenting suppressor T cells. Also blocks the complement cascade and promotes remyelination. May increase CSF IgG (10%).
IVIG has been shown to have high concentration of TSST-1 and the staphylococcal enterotoxins implicated in the pathogenesis of TSS. These antibodies may interfere with the binding of toxins that cause TSS.
Adult Dose400 mg/kg IV as single dose infused over several hours
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; IgA deficiency
InteractionsGlobulin preparation may interfere with immune response to live virus vaccine (MMR) and reduce efficacy (do not administer within 3 months of vaccine)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCheck serum IgA before IVIG (use an IgA-depleted product if deficient, eg, Gammagard S/D); infusions may increase serum viscosity and thromboembolic events; infusions may increase risk of migraine attacks, aseptic meningitis (10%), urticaria, pruritus, or petechiae (2-30 d postinfusion)
Increases risk of renal tubular necrosis in elderly patients and in patients with diabetes, volume depletion, and preexisting kidney disease; lab result changes associated with infusions include elevated antiviral or antibacterial antibody titers for 1 mo, 6-fold increase in ESR for 2-3 wk, and apparent hyponatremia



Further Outpatient Care

  • Appropriately monitor renal function, CBC count, and serum hepatic transaminase levels while patients are undergoing therapy.

Complications

  • Staphylococcus aureus infection may result in pneumonia, bone and joint infection, and infection of the heart valves.  
  • In immunocompromised hosts (eg, patients with cancer who are neutropenic and have a central venous line), 20-30% develop serious complications or fatal sepsis following catheter-related S aureus bacteremia.
  • CA-MRSA infection is more serious and is associated with thrombogenesis.

Patient Education



Medical/Legal Pitfalls

  • Scalded skin syndrome (Ritter disease) is often mistaken for erythema multiforme or toxic epidermal necrolysis, which may be treated with steroids. Misdiagnosis delays treatment and allows exfoliation to progress, and steroid therapy may potentiate bacterial superinfection. Most fatalities are associated with delay in diagnosis.
  • Another potential medical pitfall is failure to realize that, in an infant, septic arthritis of the hip and shoulder is a surgical emergency. These joints should be drained as soon as possible to prevent bony destruction. In addition, if a large amount of fibrin, tissue debris, or loculation is present, which prevents adequate drainage with needle aspiration, the joint should be surgically drained.



  1. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. Jan 4 2001;344(1):11-6. [Medline].
  2. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. Sep 1995;31(1):13-24. [Medline].
  3. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. Feb 18 1999;340(7):493-501. [Medline].
  4. CDC. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. Jul 11 1997;46(27):626-8, 635. [Medline].
  5. Jacobson JA, Kasworm E, Daly JA. Risk of developing toxic shock syndrome associated with toxic shock syndrome toxin 1 following nongenital staphylococcal infection. Rev Infect Dis. Jan-Feb 1989;11 Suppl 1:S8-13. [Medline].
  6. Abrahamian FM, Moran GJ. Methicillin-resistant Staphylococcus aureus infections. N Engl J Med. Nov 15 2007;357(20):2090; author reply 2090. [Medline].
  7. Aldin AS, Kinzl L, Eisele R. [Severe complications of Staphylococcus aureus infection in the child]. Unfallchirurg. Jan 2001;104(1):85-90. [Medline].
  8. American Academy of Pediatrics. Toxic shock syndrome. In: Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2006:660-5.
  9. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. Sep 2007;28(9):1047-53. [Medline].
  10. Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. Nov 2007;194(5):606-10. [Medline].
  11. Baartmans MG, Maas MH, Dokter J. Neonate with staphylococcal scalded skin syndrome. Arch Dis Child Fetal Neonatal Ed. Jan 2006;91(1):F25. [Medline].
  12. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. Jun 24 1992;267(24):3315-6. [Medline].
  13. Bhalla A, Aron DC, Donskey CJ. Staphylococcus aureus intestinal colonization is associated with increased frequency of S. aureus on skin of hospitalized patients. BMC Infect Dis. 2007;7:105. [Medline].
  14. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med. Apr 1999;27(4):798-801. [Medline].